QurAlis Corporation, based in Cambridge, MA, is a pioneering neurology company dedicated to finding effective precision medicines for neurodegenerative diseases such as ALS and FTD. With a relentless pursuit of knowledge and a precise attention to craft, QurAlis aims to alter the trajectory of these diseases by developing therapies that target specific components of ALS pathology and defined patient populations.
Driven by the belief that a cure or treatment should exist for every disease and every person, QurAlis has cracked the code on sporadic ALS through the identification of major disease drivers linked to TDP-43 pathology. Through their proprietary investigative platforms, QR43 and FlexASO, QurAlis is breaking through scientific barriers to discover and develop precision therapies for TDP-43-related diseases and tackle the spectrum of diseases that define ALS and other neurodegenerative conditions.
Generated from the website